MedTrace Logo

A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes

NCT00924534 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2012-01-04

No results posted yet for this study

Summary

The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SLV337 in patients with type 2 diabetes

Conditions

Interventions

DRUG

Placebo

Placebo

DRUG

SLV337

SLV337 400 mg/day

DRUG

SLV337

SLV337 800 mg/day

DRUG

SLV337

SLV337 1400 mg/day

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Abbott Products

    lead INDUSTRY

Principal Investigators

  • Francis Roy, MS · Abbott Products

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Bulgaria
  • Poland
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00924534 on ClinicalTrials.gov